StreetInsider.com News Articles

Form 8-K Tempest Therapeutics, For: Jul 17

Wed, 22 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260722/26801646.html

Form 8-K Tempest Therapeutics, For: Jul 17

Wed, 22 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260722/26801646.html

Tempest Therapeutics partners with Senlang on in vivo CAR-T candidate

Tue, 21 Jul 2026 07:02:05 -0400

Tempest Therapeutics (Nasdaq: TPST) announced a development collaboration with Hebei Senlang Biotechnology Co., Ltd. for TPST-4003, an in vivo CAR-T product candidate targeting autoimmune diseases, according to a press release issued July 21, 2026.

Under the agreement, Senlang will conduct an investigator-initiated trial of TPST-4003 in China, enrolling approximately 10 patients with myasthenia gravis or multiple sclerosis. First patient dosing is expected in the fourth quarter of 2026, with initial safety and pharmacodynamic data anticipated as early as the first half of 2027.

TPST-4003 combines CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to deplete B-cell lineages. The trial will

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tue, 21 Jul 2026 07:00:00 -0400

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications
Senlang Biotechnology, a clinical-stage cell therapy company with established expertise in CD7-targeted CAR-T development, will conduct a first-in-human investigator-initiated trial of TPST-4003 in approximately 10 patients with neurological autoimmune diseases, initially including myasthenia gravis and multiple sclerosis, with first patient dosing expected in the fourth quarter of 2026

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tue, 21 Jul 2026 07:00:00 -0400

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications
Senlang Biotechnology, a clinical-stage cell therapy company with established expertise in CD7-targeted CAR-T development, will conduct a first-in-human investigator-initiated trial of TPST-4003 in approximately 10 patients with neurological autoimmune diseases, initially including myasthenia gravis and multiple sclerosis, with first patient dosing expected in the fourth quarter of 2026

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Form DEF 14A Tempest Therapeutics, For: Jul 27

Fri, 17 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26784746.html

Form DEF 14A Tempest Therapeutics, For: Jul 27

Fri, 17 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26784746.html

Tempest Therapeutics plans in vivo CAR-T trial for late 2026

Wed, 15 Jul 2026 07:01:16 -0400

Tempest Therapeutics, Inc. (Nasdaq: TPST) announced details of its in vivo CAR-T platform and plans to advance its lead candidate, TPST-4003, into an investigator-initiated clinical trial targeting nervous system autoimmune diseases, according to a press release dated July 15, 2026.

The trial will initially focus on patients with myasthenia gravis and multiple sclerosis, with enrollment expected to cover approximately 10 patients. First patient dosing is anticipated in the fourth quarter of 2026, with initial safety and pharmacodynamic data expected in the first half of 2027 and an interim clinical update, including preliminary efficacy data, in the second half of 2027.

TPST-4003 is

Tempest Therapeutics plans in vivo CAR-T trial for late 2026

Wed, 15 Jul 2026 07:01:16 -0400

TPST-4003 is

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Wed, 15 Jul 2026 07:00:00 -0400

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach
Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indications
First investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG and MS, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027

BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) --

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Wed, 15 Jul 2026 07:00:00 -0400

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach
Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct to support broad B-cell lineage reset across multiple indications
First investigator-initiated trial expected to enroll approximately 10 patients with nervous system autoimmune diseases, including MG and MS, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027

BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) --

Form 424B3 Tempest Therapeutics,

Wed, 08 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260708/26747595.html

Form 424B3 Tempest Therapeutics,

Wed, 08 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260708/26747595.html

Form EFFECT Tempest Therapeutics,

Wed, 08 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260708/26743772.html

Form EFFECT Tempest Therapeutics,

Wed, 08 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260708/26743772.html

Form PRE 14A Tempest Therapeutics, For: Jul 27

Tue, 07 Jul 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260707/26742798.html

Form PRE 14A Tempest Therapeutics, For: Jul 27

Tue, 07 Jul 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260707/26742798.html

Tempest Therapeutics (TPST) files for 2.43M share offering by selling stockholders

Fri, 26 Jun 2026 16:05:10 -0400

Tempest Therapeutics (NASDAQ: TPST) has filed for up to 2,426,897 share offering by selling stockholders.

Tempest Therapeutics (TPST) files for 2.43M share offering by selling stockholders

Fri, 26 Jun 2026 16:05:10 -0400

Tempest Therapeutics (NASDAQ: TPST) has filed for up to 2,426,897 share offering by selling stockholders.

Form S-3 Tempest Therapeutics,

Fri, 26 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260626/26698636.html

Form S-3 Tempest Therapeutics,

Fri, 26 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260626/26698636.html

Form 4 Tempest Therapeutics, For: Mar 24 Filed by: Angel Matthew

Tue, 23 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260623/26680318.html

Form 4 Tempest Therapeutics, For: Mar 24 Filed by: Angel Matthew

Tue, 23 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260623/26680318.html

Form D Tempest Therapeutics,

Tue, 23 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26675338.html

Form D Tempest Therapeutics,

Tue, 23 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26675338.html